Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Aricept Moves Up to 3rd Place in Domestic Drugs Sales Ranking
January 12, 2009
- PSJ Symposium Calls on Researchers to Venture into New Fields
January 12, 2009
- Daiichi Sankyo to Report Valuation Loss of ¥354 Bil.
January 12, 2009
- R&D NEWS IN BRIEF
January 12, 2009
- Indirect Divisions to Support MRs at Novo Nordisk
January 12, 2009
- Market for Generics to Expand to ¥359.7 Bil. in 2010
January 12, 2009
- Kyowa Kirin to Transfer Neu-Up to Avoid Problems with AML
January 12, 2009
- Korosho to Educate Doctors on Benefits of Generics
January 12, 2009
- MediciNova Proposes Acquisition to Avigen
January 12, 2009
- New Management Team Members Appointed for Ranbaxy
January 12, 2009
- MTPC Transfers Shares of API to MCC
January 12, 2009
- Business Strategy for 2009 Announced by Agilent Technologies
January 12, 2009
- Novartis, Mochida Terminate Copromotion of Diovan
January 12, 2009
- RDKK Launches Titanium Series of Reagent Kits for Its Genome Sequencer FLX
January 12, 2009
- BUSINESS NEWS IN BRIEF
January 12, 2009
- GEYMS Launches New Models in Signa MRI Series
January 12, 2009
- Prasugrel to Be Reviewed in US in February
January 12, 2009
- MEDICAL DEVICE NEWS IN BRIEF
January 12, 2009
- Omalizumab, Maraviroc, Nalfurafine Recommended for Approval
January 12, 2009
- Korosho to Restrict Online Sales of Drugs to Class 3 Products
January 12, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…